Study of the therapeutic effects of magnesium sulfate in patients with acute migraine

Metoclopramide and Magnesium sulphate versus metoclopramide alone in managing acute migraine

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190504043470N1

Enrollment

Registered

2019-08-04

Start date

2019-09-21

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: 2 g intravenous infusion(I.V) Magnesium sulfate along with 10 mg metoclopramide. Intervention 2: Intervention group: 10 mg metoclopramide I.V injection and placebo.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Confirmed diagnosis of migraine Pain scores more than 4

Exclusion criteria

Exclusion criteria: History of drug adverse reactions Pregnancy Lactation Renal failure

Design outcomes

Primary

Measure	Time frame
Headache pain score. Timepoint: 0, 15, 30, 45 minutes after treatment. Method of measurement: VAS questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Sasani

Ahvaz University of Medical Sciences

ali.khossravi70@yahoo.com+98 21 8670 5503

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026